BSX: Boston Scientific Corp Price to Sales
Boston Scientific is expanding its presence in the cardiology and endoscopy segments driven by an aging population. The P/S ratio history confirms this trend, with the parameter stabilizing at 3.00. Growth is supported by a wide range of implantable devices for global clinics. High plant utilization and the implementation of automated product quality control ensure stability.
Analytical breakdowns for Boston Scientific Inc (BSX)
- market price and analyst price targets:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Boston Scientific|BSX - Long-Term Debt to Capital|Short-Term Debt to Capital Boston Scientific Corporation Inc.|BSX - Company Debts|Debt to Book Capitalization Ratio Boston Scientific Inc|BSX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Boston Scientific|Immediate Liquidity bostonscientific.com
- net income and valuation multiples indicators:
BSX - Company Net Income|Projected Net Profit Boston Scientific|BSX - Price to Earnings Ratio|Forward P/E Multiple Boston Scientific Corp|BSX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Boston Scientific Inc|BSX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Boston Scientific|BSX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bostonscientific.com|BSX - Earnings growth in current year|Expected net earnings per share growth next year Boston Scientific
- issuer revenue and sales details:
Fundamental company analysis:bostonscientific.com BSX
Fundamental asset selection requires comparing the market value of a business with actual sales volume to avoid overpaying for inflated expectations. This ratio measures the cost of each unit of revenue, which is critical for Boston Scientific (BSX) amid component logistics disruptions and sanction restrictions; therefore, the current P/S valuation clearly reflects the impact of operational risks on capitalization.
Who Boston Scientific competes with
Market Cap to Revenue edwards.com EW|P/S Multiple RMD (ResMed)|Insulet Corp (PODD) - Price to Sales|Zimmer - P/S Multiple|COO (CooperSurgical) - Market Cap to Revenue Ratio|ALGN: P/S Multiple|GMED - Price-to-Revenue Coefficient|TMDX (TransMedics Group, Inc.) - P/S Multiple|Market Cap to Revenue Alphatec Holdings (ATEC)|P/S Multiple AORT|P/S Multiple Enovis Inc. (ENOV)|Price-to-Revenue Ratio Integra LifeSciences IART|establishmentlabs.com - Price-to-Revenue Ratio|BBNX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IRMD (IRADIMED Corp)|EMBC: P/S Multiple|Price to Sales Tandem Corp (TNDM)|Price-to-Revenue Ratio AxoGen, Inc.|SIBN - Price-to-Revenue Multiple|Market Cap to Revenue OFIX (Orthofix)|P/S Multiple Bioventus Inc (BVS)|P/S Multiple KIDS (OrthoPediatrics)|Price-to-Revenue Coefficient Treace Corp (TMCI)|SRTA - Price-to-Revenue Ratio|Price-to-Sales Ratio CARL|RxSight (RXST) - Price-to-Revenue Ratio|Market Cap to Revenue ClearPoint Neuro|STXS (Stereotaxis Corp) - P/S Multiple|Price to Sales Neuronetics, Inc STIM|Price-to-Revenue Ratio Sight Sciences, Inc. (SGHT)|orchestrabiomed.com - Market Cap to Revenue Ratio|Anika Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume NSPR (InspireMD Inc)|Jin Medical International Ltd - P/S Multiple|VANI: Price-to-Revenue Ratio|xtantmedical.com (XTNT) - Price-to-Revenue Ratio|Price to Sales n1mtc.com (NMTC)|Price-to-Revenue Ratio Modular Medical Inc|Myomo Inc. (MYO) - Price-to-Revenue Coefficient|Market Cap to Revenue COCH (Envoy Medical, Inc)|Market Cap to Sales Volume VVOS|Price-to-Revenue Ratio enVVeno Medical NVNO|Sintx Technologies Inc (SINT) - Price to Sales|TNON - Price-to-Revenue Ratio|LFWD (ReWalk Robotics) - Market Cap to Revenue Ratio|AMIX (autonomix.com) - Market Cap to Revenue|INVO Fertility Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bone Biologics|axonics.com (AXNX) - Price-to-Revenue Coefficient|P/S Multiple BIOL|Market Cap to Revenue dynatronics.com DYNT|P/S Multiple FNA (Paragon 28)|Price-to-Revenue Coefficient INVO Bioscience Inc. (INVO)
